Minimizing the risk of posttransplant malignancy.
Recent improvements in immunosuppressive therapies have reduced the incidence of acute rejection and increased patient survival. These agents may however contribute to higher rates of mortality due to an increased risk of cardiovascular disease or malignancy. Transplant patients are immunocompromised with a reduced ability to combat the development of malignancy. The higher risk for the activity of oncoviruses may also contribute to the higher incidence and determine specific tumor types. Some immunosuppressants seem to have direct oncogenic effects. In vitro data have demonstrated that calcineurin inhibitors (CNIs) may show direct effects on tumor growth and the development of metastases. In contrast, mTOR inhibitors have demonstrated anti-tumoral properties in vitro and perhaps potent anti-angiogenic effects thereby. Recent studies and registry analyses have confirmed that mTOR inhibitors are associated with a reduced incidence of malignancies. UNOS data demonstrated that an mTOR inhibitor, with or without a CNI, is associated with a reduced incidence of tumors compared to regimens without mTOR inhibitors. The Rapamune Maintenance Regimen study demonstrated that patients receiving sirolimus-based, CNI-free therapy after CsA withdrawal at 3 months showed a reduced incidence of malignancy at 5 years posttransplant, compared with those who continued on a regimen that included CsA. In the CONVERT study, patients converted to sirolimus revealed a significantly lower malignancy rate at 24 months (3.1%) compared with those who continued CNI-based therapy (9.8%, P < .001). The elimination of CNIs and the introduction of sirolimus may, therefore, have a role to reduce the risk of cancer among posttransplant patients.
Campistol
J M
JM
Department of Nephrology and Renal Transplantation, Clinical Institute, Hospital Clínic-University of Barcelona, Barcelona, Spain. jmcampis@clinic.ub.es
D065095:Calcineurin Inhibitors; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D009369:Neoplasms / Q000453:epidemiology* / Q000517:prevention & control* / Q000821:virology; D012190:Retroviridae; D020123:Sirolimus / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D014181:Transplantation Immunology / Q000187:drug effects
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus